The production of Russia's coronavirus vaccine Sputnik V in India is expected to come fully on stream in September, the Russian Direct Investment Fund (RDIF) informed on Saturday.
"Production in India is expected to come fully onstream in September and RDIF expects India to become a major production hub for the Sputnik V vaccine with such companies as Serum Institute of India, the world's biggest vaccine producer, Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen Laboratories working to produce the vaccine," a statement issued by RDIF read.
Regarding delay in manufacturing of second component batches, they said, "Reports about Sputnik V second component production delays in India based on anonymous sources are incorrect. A number of RDIF partners in India have already produced the second component batches, which are undergoing verification at the Gamaleya Center in Russia. Transfer of technology to partners in India is also in process and there is an active exchange between Russian and Indian vaccine production specialists."
Further explaining it said, "RDIF plans to accelerate deliveries of Sputnik V and Sputnik Light to India already in August."
Earlier, Dr Reddy's said due to the spike of COVID-19 cases in Russia, the arrival of Sputnik V dose is getting delayed and the situation may ease by August end.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU